|Mr. Stephen T. Isaacs||Chairman, CEO & Pres||911.62k||N/A||1949|
|Dr. Andrea van Elsas||Chief Scientific Officer||556.5k||N/A||1967|
|Mr. Blaine E. Templeman||Chief Admin. Officer & Chief Legal Officer||649.63k||N/A||1966|
|Ms. Alexandra Santos||Exec. Director of Corp. Affairs & Investor Relations||N/A||N/A||N/A|
|Mr. Peter M. Lauer Ph.D.||Head of Molecular Biology||N/A||N/A||N/A|
Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Aduro BioTech, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 8; Compensation: 9.